FDA Clearance Tracker · P160049-S015
Stellarex 0.035OTW Drug-coated Angioplasty Balloon
Last checked: Nov 20, 2026Latest source record: Mar 25, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Mar 25, 2022
Approved
Time to decision
177 days
Received Sep 29, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160049-S015
- Device name
- Stellarex 0.035OTW Drug-coated Angioplasty Balloon
- Applicant
- The Spectranetics Corp.
- Applicant location
- Fremont, CA
- Received
- Sep 29, 2021
- Decided
- Mar 25, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160049
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for The Stellarex 0.035 inch OTW Drug-coated Angioplasty Balloon. The Stellarex 0.035 inch OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions up to 180 mm in length in superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.
Source documents
Other decisions for The Spectranetics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P160049 · Decided Jul 26, 2017 · 266 days after receipt
Device type: Drug-Eluting Peripheral Transluminal Angioplasty Catheter (ONU) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.